Search Results - Retina Today

March 2026 Supplement | Digital Supplement

From Vascular Curiosity to Neurodegenerative Disease: A Consensus Statement for the Diagnosis and Management of Macular Telangiectasia Type 2

Lejla Vajzovic, MD, FASRS; Sophie Bakri, MD; W. Lloyd Clark, MD; Diana Do, MD; Dean Eliott, MD; Roger Goldberg, MD; and Dante Pieramici, MD

March 2025 Insert

Addressing the Gaps in Duration of Treatment for Age-Related Macular Degeneration

Sustained-release tyrosine kinase inhibitors may enable retinal specialists to extend treatment intervals and reduce injection burden while maintaining visual acuity and anatomical control.

Ferhina S. Ali, MD, MPH, and Roger A. Goldberg, MD, MBA

May/June 2024 Supplement

The Evolving Treatment Paradigm in Geographic Atrophy

A panel of experts translates clinical trial data to real-world practice.

Roger A. Goldberg, MD, MBA; John W. Kitchens, MD; Eleonora Lad, MD, PhD; and Marco A. Zarbin, MD, PhD, FACS

October 2023 | Meeting Minutes

All Things Retina on the Pacific

The 9th Annual Pacific Retina Club meeting boasted mystery cases, expert lectures, and panels.

Georgia (Kaidonis) Kamboj, MBBS, PhD; Malini V. Pasricha, MD; and Mitchell J. Christensen, BS

September 2023 Supplement

Imaging Geographic Atrophy in the Age of Treatment

How can you leverage the power of imaging to provide quality care to patients with geographic atrophy without disrupting workflow?

Rishi P. Singh, MD; Roger A. Goldberg, MD, MBA; Mrinali Gupta, MD; and Katherine E. Talcott, MD

July/August 2023 Supplement

SYFOVRE® (pegcetacoplan injection): An FDA-Approved Treatment

Roger A. Goldberg, MD, MBA; Rishi Singh MD; and Charles Wykoff, MD, PhD

July/August 2023 Supplement

SYFOVRE® (pegcetacoplan injection): An FDA-Approved Treatment

Roger A. Goldberg, MD, MBA; Rishi Singh MD; and Charles Wykoff, MD, PhD

July/August 2023 Supplement

SYFOVRE® (pegcetacoplan injection): An FDA-Approved Treatment

Retina specialists discuss SYFOVRE, its 24-month data, and how on average, patients experienced a slower lesion growth rate with SYFOVRE vs sham pooled.

Roger A. Goldberg, MD, MBA; Rishi Singh MD; and Charles Wykoff, MD, PhD

July/August 2023 Supplement

SYFOVRE® (pegcetacoplan injection): An FDA-Approved Treatment

Roger A. Goldberg, MD, MBA; Rishi Singh MD; and Charles Wykoff, MD, PhD

October 2014

Novel Applications for Endoscopy

With a 23-gauge probe now available, indications are expanding.

Roger A. Goldberg, MD, MBA

October 2014

Novel Applications for Endoscopy

With a 23-gauge probe now available, indications are expanding.

Roger A. Goldberg, MD, MBA